Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
The classification of Oral Mucositis Drugs includes Mouthwash, Pain Control Medication and Other, the sales of Mouthwash are 16.9 million units, with its market share 48.8%. And the sales market share of Pain Control Medication is 38% in 2017.
Oral Mucositis Drugs is widely used to Chemotherapy Oral Mucositis and Radiotherapy Oral Mucositis. The most proportion of Oral Mucositis Drugs is to Radiotherapy Oral Mucositis, and the proportion is about 69.6% in 2017.
North America region is the largest supplier of Oral Mucositis Drugs, with a production market share nearly 53.6% in 2017. Europe is the second largest supplier of Oral Mucositis Drugs, enjoying production market share nearly 33.2% in 2017.
North America is the largest sales place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 26.9% in 2017. China is an important market of Oral Mucositis Drugs in Asia, accounting for 7.6% sales market share of global market.

According to this study, over the next five years the Oral Mucositis Drugs market will register a 8.0% CAGR in terms of revenue, the global market size will reach US$ 640 million by 2024, from US$ 400 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Oral Mucositis Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Mucositis Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Oral Mucositis Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
Mouthwash
Pain?Control?Medication
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
Chemotherapy
Radiotherapy

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Biovitrum?
Valeant Pharmaceuticals
EUSA?Pharma
Camurus
Mission Pharmacal
Clinigen Group
Midatech Pharma
Alliance Pharma
AMAG Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Oral Mucositis Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Oral Mucositis Drugs market by identifying its various subsegments.
Focuses on the key global Oral Mucositis Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Oral Mucositis Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Oral Mucositis Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.